{"protocolSection":{"identificationModule":{"nctId":"NCT04370028","orgStudyIdInfo":{"id":"DIAMANT"},"organization":{"fullName":"Materia Medica Holding","class":"INDUSTRY"},"briefTitle":"Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders","officialTitle":"All-Russian Observational Non-interventional Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders","acronym":"DIAMANT"},"statusModule":{"statusVerifiedDate":"2020-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-01","type":"ACTUAL"},"completionDateStruct":{"date":"2017-01","type":"ACTUAL"},"studyFirstSubmitDate":"2020-04-28","studyFirstSubmitQcDate":"2020-04-28","studyFirstPostDateStruct":{"date":"2020-04-30","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-12-06","resultsFirstSubmitQcDate":"2021-03-09","resultsFirstPostDateStruct":{"date":"2021-03-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-03-09","lastUpdatePostDateStruct":{"date":"2021-03-10","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Materia Medica Holding","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"An open-label, prospective, observational, multicenter study. The study enrolls adult outpatients with CCI from 8 federal districts of the Russian Federation.","detailedDescription":"Medical data (demographic and clinical characteristics - diagnosis, MoCA test results) are collected from patients to whom Divaza is prescribed to be taken according to the following regimen: 2 tablets 3 times per day for 12 weeks.\n\nNeurologists assess the patients' cognitive functions with MoCA scale before starting therapy with Divaza (visit 1) and 12 weeks after the treatment (visit 2).\n\nThe efficacy of Divaza for the treatment of cognitive impairment in patients with chronic cerebral ischemia (CCI) is evaluated.\n\nSafety is assessed based on the frequency and severity of adverse events. In addition, the relationship between MoCA test performance and gender or regional social and economic factors is evaluated."},"conditionsModule":{"conditions":["Chronic Cerebral Ischemia"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":2583,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Divaza","description":"Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.","interventionNames":["Drug: Divaza"]}],"interventions":[{"type":"DRUG","name":"Divaza","description":"Oral administration.","armGroupLabels":["Divaza"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean MoCA Score at Week 1 and the End of the 12-week Therapy","description":"MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome).MoCA test allows to evaluate the presence of cognitive impairment","timeFrame":"week 1 to 12 week"}],"secondaryOutcomes":[{"measure":"The Number of Patients With a MoCA Score <26 at 12 Week","description":"The number of patients with mild cognitive impairment. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","timeFrame":"12 week"},{"measure":"The Number of Patients With a MoCA Score ≤ 17 at the End of the 12-week Therapy","description":"The number of patients with dementia. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","timeFrame":"week1 to week 12"},{"measure":"The Dynamics of Mean MoCA Score in Each Age Group","description":"Age groups:young \\<35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","timeFrame":"week1 to week 12"},{"measure":"The Number of Patients With a MoCA Score Improvement (Increase in Scores) in Age Groups","description":"Age groups:young \\<35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","timeFrame":"week1 to week 12"}],"otherOutcomes":[{"measure":"The Relationship Between Cognitive Impairment and Patients' Gender","description":"Evaluation of the relationship between baseline MoCA test results and gender. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","timeFrame":"Data measured at baseline"},{"measure":"The Relationship Between Cognitive Impairment and Regional Social/Economic Factors","description":"Evaluation of the relationship between baseline MoCA test results and regional developmental social or economic indicators (poverty, infant mortality, migration, life expectancy, innovation rate, professional development, number of university students, number of R\\&D personnel, resources spent on R\\&D, number of doctors, number of hospitals and outpatient clinics, hospital capacity, fertility rate, quality of life index,income).\n\nRelevance of factors (unitless value) provided. The higher the more influential the factor is.\n\nRelevance was assessed with Boruta approach:\n\nKURSA, Miron B.; RUDNICKI, Witold R.. Feature Selection with the Boruta Package. Journal of Statistical Software, \\[S.l.\\], v. 36, Issue 11, p. 1 - 13, sep. 2010. ISSN 1548-7660. Available at: \\<http://www.jstatsoft.org/v036/i11\\>. Date accessed: 24 nov. 2020. doi:http://dx.doi.org/10.18637/jss.v036.i11.","timeFrame":"Data measured at baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients of either gender aged 18+ years.\n2. Diagnosis of chronic cerebral ischemia (CCI) based on the clinical history of underlying vascular disease(atherosclerosis and/or arterial hypertension) and neurological signs.\n3. Unchanged basic therapy of CCI and underlying vascular disease for a previous 3 month.\n4. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Other neurological diseases.\n2. Any known allergy to/intolerance of any constituent of the medication.\n3. Pregnancy, breast-feeding.\n4. Participation in other clinical trials for 3 months prior to enrollment in this study.\n5. The patient is related to the research personnel of the investigative sites that are directly involved in the study, or is the immediate relative of the investigator, or the employee of OOO NPF Materia Medica Holding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Adult CCI outpatients with cognitive impairment (MoCA score \\<26) or without one (MoCA score ≥ 26) recieving unchanged basic therapy of CCI and underlying vascular disease for a 3 month previous to the onset of the study. Diagnosis of сhronic cerebral ischemia (CCI) was based on the clinical history of underlying vascular disease(atherosclerosis and/or arterial hypertension) and neurological signs. Vascular nature of cognitive impairment in patients with MoCA\\<26 was determined according to NINDS-AIREN criteria.","samplingMethod":"PROBABILITY_SAMPLE"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Recruitment period: October 2016 January 2017 Location: outpatient clinics from 8 federal districts of the Russian Federation","groups":[{"id":"FG000","title":"Divaza Treatment Group","description":"All enrolled patients received Divaza 2 tablets 3 times per day for 12 weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2583"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1876"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"707"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"695"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"9"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety was assessed using the data of all 2583 patients. Within each efficacy and demographic analysis only complete cases approach was used, therefore the number of patients analyzed in efficacy analysis was fewer than 1876","groups":[{"id":"BG000","title":"Divaza Treatment Group","description":"All participants received Divaza treatment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1876"}]}],"measures":[{"title":"Age, Continuous","populationDescription":"Age was not reported for 23 patients.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1853"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"65.7","spread":"19.1"}]}]}]},{"title":"Age, Customized","populationDescription":"Age was not reported for 23 patients","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Young (<35 yo)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1853"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}]},{"title":"Middle aged (35-59 yo)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1853"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"501"}]}]},{"title":"Elderly (60-75 yo)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1853"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"1062"}]}]},{"title":"Senile (75-90 yo)","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1853"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"265"}]}]}]},{"title":"Sex: Female, Male","populationDescription":"Within each analysis only complete cases approach was used.Sexual identity of 29 patients was not specified.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1847"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1139"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"708"}]}]}]},{"title":"Baseline MoCA score","description":"MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome).MoCA test allows to evaluate the presence of cognitive impairment","populationDescription":"Baseline MoCA scores were not reported in 21 patients.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1855"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"19.4","spread":"5.1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean MoCA Score at Week 1 and the End of the 12-week Therapy","description":"MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome).MoCA test allows to evaluate the presence of cognitive impairment","populationDescription":"MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"week 1 to 12 week","groups":[{"id":"OG000","title":"Divaza Treatment Group","description":"All analyzed participants received Divaza treatment 2 tablets 3 times per day for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1855"}]}],"classes":[{"title":"1 week","categories":[{"measurements":[{"groupId":"OG000","value":"19.42","spread":"5.13"}]}]},{"title":"12 week","categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"4.6"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.00001","statisticalMethod":"t-test, 2 sided","statisticalComment":"Paired test was performed","paramType":"Mean Difference (Net)","paramValue":"4.57","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.42","ciUpperLimit":"4.72"}]},{"type":"SECONDARY","title":"The Number of Patients With a MoCA Score <26 at 12 Week","description":"The number of patients with mild cognitive impairment. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","populationDescription":"MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"12 week","groups":[{"id":"OG000","title":"Divaza Treatment Group","description":"All analyzed participants received Divaza treatment 2 tablets 3 times per day for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1855"}]}],"classes":[{"title":"week 1","categories":[{"measurements":[{"groupId":"OG000","value":"1676"}]}]},{"title":"week 12","categories":[{"measurements":[{"groupId":"OG000","value":"1048"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Odds ratio of occuring MoCA score \\<26 was assessed","nonInferiorityType":"SUPERIORITY","pValue":"<0.00001","statisticalMethod":"Fisher Exact","paramType":"Odds Ratio (OR)","paramValue":"7.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"6.01","ciUpperLimit":"8.67","estimateComment":"OR estimated (week 1 to week 12) the higher the better"}]},{"type":"SECONDARY","title":"The Number of Patients With a MoCA Score ≤ 17 at the End of the 12-week Therapy","description":"The number of patients with dementia. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","populationDescription":"MoCA scores were not reported in 21 patients at least at one timepoint (excluded from analysis)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"week1 to week 12","groups":[{"id":"OG000","title":"Divaza Treatment Group","description":"All analyzed participants received Divaza treatment 2 tablets 3 times per day for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1855"}]}],"classes":[{"title":"week 1","categories":[{"measurements":[{"groupId":"OG000","value":"489"}]}]},{"title":"week 12","categories":[{"measurements":[{"groupId":"OG000","value":"117"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Odds ratio of occuring MoCA score \\<17 was assessed","nonInferiorityType":"SUPERIORITY","pValue":"<0.00001","statisticalMethod":"Fisher Exact","paramType":"Odds Ratio (OR)","paramValue":"5.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.28","ciUpperLimit":"6.64","estimateComment":"OR estimated (week 1 to week 12) the higher the better"}]},{"type":"SECONDARY","title":"The Dynamics of Mean MoCA Score in Each Age Group","description":"Age groups:young \\<35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","populationDescription":"Patients who did not reported age or both MoCA scores were excluded from analysis","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"week1 to week 12","groups":[{"id":"OG000","title":"Young Patients<35 yo","description":"Young Patients\\<35 yo treated with Divaza"},{"id":"OG001","title":"Middle-aged Patients 35-59 yo","description":"Middle-aged patients 35-59 yo treated with Divaza"},{"id":"OG002","title":"Elderly Patients 60-75 yo","description":"Elderly patients 60-75 yo treated with Divaza"},{"id":"OG003","title":"Senile Patients 75-90 yo","description":"Senile patients 75-90 yo received Divaza"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"501"},{"groupId":"OG002","value":"1062"},{"groupId":"OG003","value":"265"}]}],"classes":[{"title":"week 1","categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"5.6"},{"groupId":"OG001","value":"20.94","spread":"4.93"},{"groupId":"OG002","value":"19.39","spread":"4.7"},{"groupId":"OG003","value":"16.23","spread":"5.42"}]}]},{"title":"week 12","categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":"5.6"},{"groupId":"OG001","value":"25.7","spread":"3.6"},{"groupId":"OG002","value":"23.9","spread":"4.2"},{"groupId":"OG003","value":"20.7","spread":"5.6"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Change of mean MoCA score","nonInferiorityType":"SUPERIORITY","pValue":"<0.07","statisticalMethod":"ANOVA","paramType":"Mean Difference (Net)","paramValue":"2.375","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.21","ciUpperLimit":"4.96"},{"groupIds":["OG001"],"groupDescription":"Change of mean MoCA score","nonInferiorityType":"SUPERIORITY","pValue":"<0.01","statisticalMethod":"ANOVA","paramType":"Mean Difference (Net)","paramValue":"4.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.17","ciUpperLimit":"5.31"},{"groupIds":["OG002"],"groupDescription":"Change of mean MoCA score","nonInferiorityType":"SUPERIORITY","pValue":"<0.01","statisticalMethod":"ANOVA","paramType":"Mean Difference (Net)","paramValue":"4.55","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.16","ciUpperLimit":"4.94"},{"groupIds":["OG003"],"groupDescription":"Change of mean MoCA score","nonInferiorityType":"SUPERIORITY","pValue":"<0.01","statisticalMethod":"ANOVA","paramType":"Mean Difference (Net)","paramValue":"4.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.7","ciUpperLimit":"5.27"}]},{"type":"SECONDARY","title":"The Number of Patients With a MoCA Score Improvement (Increase in Scores) in Age Groups","description":"Age groups:young \\<35 yo, middle-aged - 35-59 yo, elderly - 60-75 yo, senile - 75-90 yo MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","populationDescription":"Patients who did not reported age or both MoCA scores were excluded from analysis","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"week1 to week 12","groups":[{"id":"OG000","title":"Young Patients<35 yo","description":"Young Patients\\<35 yo treated with Divaza"},{"id":"OG001","title":"Middle-aged Patients 35-59 yo","description":"Middle-aged patients 35-59 yo treated with Divaza"},{"id":"OG002","title":"Elderly Patients 60-75 yo","description":"Elderly patients 60-75 yo treated with Divaza"},{"id":"OG003","title":"Senile Patients 75-90 yo","description":"Senile patients 75-90 yo received Divaza"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"501"},{"groupId":"OG002","value":"1062"},{"groupId":"OG003","value":"265"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"199"},{"groupId":"OG002","value":"616"},{"groupId":"OG003","value":"214"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Relationship Between Cognitive Impairment and Patients' Gender","description":"Evaluation of the relationship between baseline MoCA test results and gender. MoCA - Montreal Cognitive Assessment (0-30 scores, higher scores mean a better outcome)","populationDescription":"Patients who did not reported sex or baseline MoCA score were excluded from analysis","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Data measured at baseline","groups":[{"id":"OG000","title":"Female","description":"Female patients treated with Divaza"},{"id":"OG001","title":"Male","description":"Male patients treated with Divaza"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1139"},{"groupId":"OG001","value":"708"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"5.09"},{"groupId":"OG001","value":"18.9","spread":"5.13"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0011","statisticalMethod":"ANOVA","paramType":"Mean Difference (Net)","paramValue":"0.803","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.321","ciUpperLimit":"1.28","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.246"}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Relationship Between Cognitive Impairment and Regional Social/Economic Factors","description":"Evaluation of the relationship between baseline MoCA test results and regional developmental social or economic indicators (poverty, infant mortality, migration, life expectancy, innovation rate, professional development, number of university students, number of R\\&D personnel, resources spent on R\\&D, number of doctors, number of hospitals and outpatient clinics, hospital capacity, fertility rate, quality of life index,income).\n\nRelevance of factors (unitless value) provided. The higher the more influential the factor is.\n\nRelevance was assessed with Boruta approach:\n\nKURSA, Miron B.; RUDNICKI, Witold R.. Feature Selection with the Boruta Package. Journal of Statistical Software, \\[S.l.\\], v. 36, Issue 11, p. 1 - 13, sep. 2010. ISSN 1548-7660. Available at: \\<http://www.jstatsoft.org/v036/i11\\>. Date accessed: 24 nov. 2020. doi:http://dx.doi.org/10.18637/jss.v036.i11.","populationDescription":"Incomplete data (with respect to used variables) was excluded","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"unitless feature importance","timeFrame":"Data measured at baseline","groups":[{"id":"OG000","title":"Divaza Treatment Group","description":"All enrolled patients received Divaza 2 tablets 3 times per day for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1797"}]}],"classes":[{"title":"Age","categories":[{"measurements":[{"groupId":"OG000","value":"39.85","lowerLimit":"39.48","upperLimit":"41.03"}]}]},{"title":"Poverty percentage","categories":[{"measurements":[{"groupId":"OG000","value":"8.36","lowerLimit":"7.66","upperLimit":"8.9"}]}]},{"title":"Infant mortality","categories":[{"measurements":[{"groupId":"OG000","value":"7.97","lowerLimit":"7.53","upperLimit":"8.33"}]}]},{"title":"Migration index","categories":[{"measurements":[{"groupId":"OG000","value":"7.92","lowerLimit":"7.23","upperLimit":"8.42"}]}]},{"title":"Life expectancy","categories":[{"measurements":[{"groupId":"OG000","value":"6.42","lowerLimit":"5.86","upperLimit":"7.15"}]}]},{"title":"Professional development index","categories":[{"measurements":[{"groupId":"OG000","value":"6.13","lowerLimit":"5.52","upperLimit":"6.68"}]}]},{"title":"Number of R&D personnel","categories":[{"measurements":[{"groupId":"OG000","value":"5.81","lowerLimit":"4.7","upperLimit":"6.37"}]}]},{"title":"Hospitals number","categories":[{"measurements":[{"groupId":"OG000","value":"5.65","lowerLimit":"5.16","upperLimit":"6.09"}]}]},{"title":"R&D expenditures","categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"5","upperLimit":"6.31"}]}]},{"title":"Innovation rate","categories":[{"measurements":[{"groupId":"OG000","value":"5.56","lowerLimit":"5.12","upperLimit":"6.04"}]}]},{"title":"Hospitals capacity","categories":[{"measurements":[{"groupId":"OG000","value":"4.89","lowerLimit":"4.46","upperLimit":"5.16"}]}]},{"title":"Fertility rate","categories":[{"measurements":[{"groupId":"OG000","value":"4.87","lowerLimit":"4.3","upperLimit":"5.41"}]}]},{"title":"QoL index","categories":[{"measurements":[{"groupId":"OG000","value":"4.85","lowerLimit":"4.06","upperLimit":"5.54"}]}]},{"title":"Outpatient clinics","categories":[{"measurements":[{"groupId":"OG000","value":"4.73","lowerLimit":"4.32","upperLimit":"5.59"}]}]},{"title":"Nursing personnel","categories":[{"measurements":[{"groupId":"OG000","value":"4.69","lowerLimit":"3.87","upperLimit":"5.63"}]}]},{"title":"Income level","categories":[{"measurements":[{"groupId":"OG000","value":"3.83","lowerLimit":"3","upperLimit":"4.59"}]}]},{"title":"University students","categories":[{"measurements":[{"groupId":"OG000","value":"3.79","lowerLimit":"3.19","upperLimit":"4.33"}]}]},{"title":"Number of doctors","categories":[{"measurements":[{"groupId":"OG000","value":"3.78","lowerLimit":"3.17","upperLimit":"4.19"}]}]},{"title":"shadowMax (reference zero-importance feature)","categories":[{"measurements":[{"groupId":"OG000","value":"2.66","lowerLimit":"1.83","upperLimit":"3.11"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"12 weeks","description":"AEs were collected from all patients received a single dose of Divaza according to patient's complaints and physical examination.","eventGroups":[{"id":"EG000","title":"Divaza Treatment Group","description":"All enrolled patients received Divaza 2 tablets 3 times per day for 12 weeks","deathsNumAffected":0,"deathsNumAtRisk":2583,"seriousNumAffected":0,"seriousNumAtRisk":2583,"otherNumAffected":17,"otherNumAtRisk":2583}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2583}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2583}]},{"term":"Somnolence","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2583}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2583}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2583}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2583}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2583}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2583}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2583}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2583}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Mikhail Putilovskiy, MD, PhD","organization":"OOO NPF Materia Medica Holding","email":"PutilovskiyMA@materiamedica.ru","phone":"+74952761575","phoneExt":"302"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"},{"id":"D000060825","term":"Cognitive Dysfunction"},{"id":"D000003072","term":"Cognition Disorders"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000020521","term":"Stroke"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M10233","name":"Ischemia","asFound":"Ischemia","relevance":"HIGH"},{"id":"M5991","name":"Cognition Disorders","asFound":"Cognitive Disorders","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Ischemia","relevance":"HIGH"},{"id":"M5484","name":"Brain Ischemia","asFound":"Cerebral Ischemia","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M29395","name":"Cognitive Dysfunction","asFound":"Cognitive Disorders","relevance":"HIGH"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":true}